|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
21
|
|
pubmed:dateCreated |
2009-5-27
|
|
pubmed:abstractText |
Mutations in the NPM1 gene represent the most frequent genetic alterations in patients with acute myeloid leukemia (AML) and are associated with a favorable outcome. In 690 normal karyotype (NK) AML patients the complete remission rates (CRs) and the percentage of patients with adequate in vivo blast cell reduction 1 week after the end of the first induction cycle were significantly higher in NPM1(+) (75% and 80%, respectively) than in NPM1(-) (57% and 57%, respectively) patients, but were unaffected by the FLT3-ITD status. Multivariate analyses revealed the presence of a NPM1 mutation as an independent positive prognostic factor for the achievement of an adequate day-16 blast clearance and a CR. In conclusion, NPM1(+) blast cells show a high in vivo sensitivity toward induction chemotherapy irrespective of the FLT3-ITD mutation status. These findings provide insight into the pathophysiology and help to understand the favorable clinical outcome of patients with NPM1(+) AML.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1528-0020
|
|
pubmed:author |
pubmed-author:BenthausTobiasT,
pubmed-author:BerdelWolfgang EWE,
pubmed-author:BohlanderStefan KSK,
pubmed-author:BraessJanJ,
pubmed-author:BuechnerThomasT,
pubmed-author:BuskeChristianC,
pubmed-author:DufourAnnikaA,
pubmed-author:Feuring-BuskeMichaelaM,
pubmed-author:FritschSusanneS,
pubmed-author:HeineckeAchimA,
pubmed-author:HiddemannWolfgangW,
pubmed-author:HosterEvaE,
pubmed-author:MellertGudrunG,
pubmed-author:SauerlandMaria CMC,
pubmed-author:SchneiderFriederikeF,
pubmed-author:SchneiderStephanieS,
pubmed-author:SpiekermannKarstenK,
pubmed-author:UnterhaltMichaelM,
pubmed-author:WoermannBernhard JBJ,
pubmed-author:ZellmeierEvelinE
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
21
|
|
pubmed:volume |
113
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5250-3
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:19279329-Antineoplastic Agents,
pubmed-meshheading:19279329-Blast Crisis,
pubmed-meshheading:19279329-Humans,
pubmed-meshheading:19279329-Inverted Repeat Sequences,
pubmed-meshheading:19279329-Karyotyping,
pubmed-meshheading:19279329-Killer Cells, Natural,
pubmed-meshheading:19279329-Leukemia, Myeloid, Acute,
pubmed-meshheading:19279329-Mutation,
pubmed-meshheading:19279329-Myelodysplastic Syndromes,
pubmed-meshheading:19279329-Nuclear Proteins,
pubmed-meshheading:19279329-Prognosis,
pubmed-meshheading:19279329-Remission Induction,
pubmed-meshheading:19279329-fms-Like Tyrosine Kinase 3
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS).
|
|
pubmed:affiliation |
Department of Medicine III, University Hospital Munich, Germany.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
